To characterize the anti‐fibrotic properties of these EVs in terms of IPF treatment (Araya & Nishimura, 2010), we uses lung fibroblasts (LFs) to examine EV effects on TGF‐β‐induced myofibroblast differentiation (Figure 1b). This evidence concerns the gene TGFB1 and idiopathic pulmonary fibrosis.